More tools:Markets·Screener·Research·Chat

Addex Therapeutics Ltd American Depositary Shares (ADXN) Financial Statements

Addex Therapeutics Ltd American Depositary Shares
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00R48SV18
XNAS · usd
3.71▲ 0.01 (0.27%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close3.70
Day's Range3.53 – 3.84
52-Week Range3.40 – 12.05
Volume60.1K
Avg Volume279.8K
Share Statistics
Shares Outstanding
Employees2
ExchangeXNAS
Listed2020-01-29
Share count as of December 31, 2025
Loading Income Statement…
Key questions about Addex Therapeutics Ltd American Depositary Shares (ADXN)
What is Addex Therapeutics Ltd American Depositary Shares's Market Cap?
Addex Therapeutics Ltd American Depositary Shares's Market Cap is $548.5M, based on as-reported figures from SEC (XBRL) filings.
What is Addex Therapeutics Ltd American Depositary Shares's Enterprise Value?
Addex Therapeutics Ltd American Depositary Shares's Enterprise Value is $546.4M, based on as-reported figures from SEC (XBRL) filings.
What is Addex Therapeutics Ltd American Depositary Shares's Price / Sales?
Addex Therapeutics Ltd American Depositary Shares's Price / Sales is 14522.0×, based on as-reported figures from SEC (XBRL) filings.
What is Addex Therapeutics Ltd American Depositary Shares's EV / Revenue?
Addex Therapeutics Ltd American Depositary Shares's EV / Revenue is 14467.4×, based on as-reported figures from SEC (XBRL) filings.
What is Addex Therapeutics Ltd American Depositary Shares's EV / EBITDA?
Addex Therapeutics Ltd American Depositary Shares's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Addex Therapeutics Ltd American Depositary Shares's Revenue (TTM)?
Addex Therapeutics Ltd American Depositary Shares's Revenue (TTM) is $37.8K, based on as-reported figures from SEC (XBRL) filings.
What is Addex Therapeutics Ltd American Depositary Shares's Net Income (TTM)?
Addex Therapeutics Ltd American Depositary Shares's Net Income (TTM) is -$8.5M, based on as-reported figures from SEC (XBRL) filings.
What is Addex Therapeutics Ltd American Depositary Shares's EBITDA?
Addex Therapeutics Ltd American Depositary Shares's EBITDA is -$3.5M, based on as-reported figures from SEC (XBRL) filings.
What is Addex Therapeutics Ltd American Depositary Shares's Diluted EPS (TTM)?
Addex Therapeutics Ltd American Depositary Shares's Diluted EPS (TTM) is -0.06, based on as-reported figures from SEC (XBRL) filings.
What is Addex Therapeutics Ltd American Depositary Shares's EBITDA Margin?
Addex Therapeutics Ltd American Depositary Shares's EBITDA Margin is -9362.5%, based on as-reported figures from SEC (XBRL) filings.
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017
Consolidated Statements of Profit or Loss
Revenue from contract with customer
Other income
Operating costs
Research and development
General and administration
Total operating costs
Operating loss
Interest Income—
Finance expense
Finance result
Share of net loss of investments accounted for using the equity method
Net loss before tax from continuing operations
Net loss from continuing operations
Net profit / (loss) from discontinued operations (attributable to equity holders of the Group)
Net profit / (loss) for the period
Basic profit / (loss) per share for profit/(loss) attributable to the ordinary equity holders of the Company
Diluted profit / (loss) per share for profit/ (loss) attributable to the ordinary equity holders of the Company